R. A. Huddart Et Al. , "PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer," FUTURE ONCOLOGY , vol.17, pp.137-149, 2021
Huddart, R. A. Et Al. 2021. PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. FUTURE ONCOLOGY , vol.17 , 137-149.
Huddart, R. A., Siefker-Radtke, A. O., Balar, A., Bilen, M. A., Powles, T., Bamias, A., ... Castellano, D.(2021). PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. FUTURE ONCOLOGY , vol.17, 137-149.
Huddart, Robert Et Al. "PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer," FUTURE ONCOLOGY , vol.17, 137-149, 2021
Huddart, Robert A. Et Al. "PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer." FUTURE ONCOLOGY , vol.17, pp.137-149, 2021
Huddart, R. A. Et Al. (2021) . "PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer." FUTURE ONCOLOGY , vol.17, pp.137-149.
@article{article, author={Robert A. Huddart Et Al. }, title={PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer}, journal={FUTURE ONCOLOGY}, year=2021, pages={137-149} }